EAST WINDSOR, N.J. — Aurobindo Pharma USA (Aurobindo) has proposed the acquisition of Lannett Co. (Lannett). The company says it anticipates closing the acquisition towards the middle of calendar 2026, subject to regulatory approval.
"Over the coming months, we will be providing additional updates on this exciting acquisition and how we expect it to enable us to better serve you, our valued customer," said Paul McMahon, president, APUSA Oral Solids Division at Aurobindo. "In the meantime, until the transaction closes, it will be business as usual in every respect with both Aurobindo and Lannett continuing to operate as separate entities. Please continue to work with your respective points of contact at Aurobindo and Lannett for any of your normal day-to-day business needs regarding the respective product portfolios, operational and transactional matters, etc," he added.
Aurobindo to purchase Lannett Co.
The company says it anticipates closing the acquisition towards the middle of calendar 2026, subject to regulatory approval.
Latest
U.S. probiotic supplements market set for steady growth
U.S. retailers face growing demand for transparency in strain labeling and CFU counts among informed supplement consumers.
U.S.-driven growth to propel global cosmetics market to $704B by 2032
As AI-powered diagnostics, AR try-ons, and science-backed formulas continue to grow, U.S. retail will be a key driver in shaping global beauty innovation through 2032.
California Gold Nutrition Sport Pure Creatine Monohydrate named top creatine in new report
The publisher highlighted creatine monohydrate’s clinical support for strength, high-intensity performance, and lean body mass when combined with resistance training. It also emphasized manufacturing transparency and controlled distribution as key in selecting top products.
Walgreens Specialty Pharmacy earns full Specialty Pharmacy Accreditation from URAC
These accreditations reinforce the company’s dedication to delivering quality, compassionate patient care.